Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

被引：0
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Khoury, H. Jean [2 ]
Kantarjian, Hagop M. [3 ]
Lipton, Jeffrey H. [4 ]
Kim, Dong-Wook [5 ]
Schafhausen, Philippe [6 ]
Matczak, Ewa M. [7 ]
Leip, Eric [8 ]
Noonan, Kay [9 ]
Bruemmendorf, Tim H. [6 ,10 ]
Cortes, Jorge E. [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Seoul St Marys Hosp, Seoul, South Korea
[6] Univ Canc Ctr Hamburg, Hubertus Wald Tumor Ctr, Hamburg, Germany
[7] Pfizer Inc, New York, NY USA
[8] Pfizer Inc, Cambridge, MA USA
[9] Pfizer Inc, Groton, CT 06340 USA
[10] RWTH Aachen Univ Hosp, Aachen, Germany
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)
    Brummendorf, T. H.
    Cortes, J. E.
    Kantarjian, H.
    Gambacorti-Passerini, C.
    Baccarani, M.
    Kim, D.
    Zaritskey, A.
    Navarro, J.
    Rapoport, A.
    Dorlhiac-Llacer, P. E.
    Milone, J.
    Zanichelli, M.
    Besson, N.
    Leip, E.
    Kelly, V.
    Khoury, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Conlan, Maureen G.
    Leip, Eric
    Turnbull, Kathleen
    Gambacorti-Passerini, Carlo
    Lipton, Jeff H.
    BLOOD, 2013, 122 (21)
  • [3] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
    Khoury, H. Jean
    Kim, Dong-Wook
    Zaritskey, Andrey
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Navarro, Juan
    Rapoport, Aaron P.
    Dorlhiac-Llacer, Pedro Enrique
    Zanichelli, Maria
    Kelly, Virginia
    Besson, Nadine
    McMullan, Trevor
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 391 - 391
  • [4] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
    Gambacorti-Passerini, C.
    Cortes, J.
    Zaritskey, A.
    Bullorsky, E.
    Navarro, J.
    Khoury, H.
    Besson, N.
    McMullan, T.
    Arkin, S.
    Bruemmendorf, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
  • [5] Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
    Khoury, H. Jean
    Gambacorti-Passerini, Carlo
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Marin, David
    Dorlhiac-Llacer, Pedro E.
    Zaritskey, Andrey
    Navarro, Juan
    Bullorsky, Eduardo O.
    Assouline, Sarit
    Leip, Eric
    Kelly, Virginia
    Turnbull, Kathleen
    Besson, Nadine
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [6] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
    Khoury, H. J.
    Kim, D.
    Zaritskey, A.
    Apperley, J.
    Besson, N.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [8] Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Zeremski, Mirjana
    Shapiro, Mark
    Leip, Eric
    Gambacorti-Passerini, Carlo
    Lipton, Jeffrey H.
    BLOOD, 2014, 124 (21)
  • [9] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    Khoury, H. Jean
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Gambacorti-Passerini, Carlo
    Baccarani, Michele
    Kim, Dong-Wook
    Zaritskey, Andrey
    Countouriotis, Athena
    Besson, Nadine
    Leip, Eric
    Kelly, Virginia
    Bruemmendorf, Tim H.
    BLOOD, 2012, 119 (15) : 3403 - 3412
  • [10] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
    Cortes, Jorge E.
    Khoury, Hanna J.
    Kantarjian, Hagop M.
    Lipton, Jeff H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : 1206 - 1214
12345